Remimazolam use in obstetric patients: a single-center retrospective study (2021–2024)
- 8 August 2025
- journal article
- Published by Elsevier in International Journal of Obstetric Anesthesia
- Vol. 64, 104750
Abstract
No abstract availableKeywords
Funding Information
- National Center for Advancing Translational Sciences
- National Institutes of Health
- Mayo Clinic (UL1TR002377)
This publication has 19 references indexed in Scilit:
- Effectiveness of Remimazolam on Preventing Adverse Reactions Caused by Carboprost Tromethamine During Cesarean SectionClinical Therapeutics, 2024
- The safety of benzodiazepines and related drugs during pregnancy: an updated meta-analysis of cohort studiesArchives of Gynecology and Obstetrics, 2024
- Remimazolam administration for severe anxiety during a neuraxial block placement in active laborInternational Journal of Obstetric Anesthesia, 2024
- Benzodiazepine Use During Pregnancy and Risk of MiscarriageJAMA Psychiatry, 2024
- Risk of major malformations in infants after first‐trimester exposure to benzodiazepines: Results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric MedicationsDepression and Anxiety, 2022
- “Sleep and Keep”: Dispelling Myths of “Pump and Dump” from an Anesthesiologist's PerspectiveJournal of Women's Health, 2020
- Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth OutcomesJAMA Psychiatry, 2017
- Remimazolam: Pharmacologic Considerations and Clinical Role in AnesthesiologyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Neonatal Benzodiazepines Exposure during BreastfeedingThe Journal of Pediatrics, 2012
- Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancyAmerican Journal of Obstetrics and Gynecology, 2009